Laurie Black
Family · Columbus, INNPI 1376109736
Payments from drug & device makers
Across 153 payments — averaging $31.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$2K
- AbbVie$714
- UCB, Inc.$369
- Lilly USA, LLC$163
- Biohaven Pharmaceutical Holding Company Ltd.$142
- Pfizer$138
- plus $1K from 31 others
What the payments were for
- Travel & lodging$1,33728%
- Food & beverage$3,40671%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 7 | $1,776 |
| AbbVie | 33 | $714 |
| UCB, Inc. | 15 | $369 |
| Lilly USA, LLC | 9 | $163 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $142 |
| Pfizer | 8 | $138 |
| Harmony Biosciences LLC | 3 | $127 |
| AstraZeneca | 5 | $126 |
| Amgen | 6 | $118 |
| Boston Scientific | 1 | $91 |
| Sunovion Pharmaceuticals Inc. | 13 | $88 |
| Novartis | 4 | $87 |
| Eisai Inc. | 4 | $74 |
| Edwards Lifesciences | 1 | $69 |
| Lundbeck LLC | 3 | $64 |
| Amneal Pharmaceuticals LLC | 3 | $58 |
| Inspire Medical Systems, Inc. | 2 | $49 |
| SK Life Science, Inc. | 2 | $48 |
| Banner Life Sciences, LLC | 3 | $45 |
| Neurocrine Biosciences, Inc. | 2 | $43 |
| Bristol Myers Squibb | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Argenx US, Inc. | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Tanabe Pharma America, Inc. | 1 | $26 |
| Johnson & Johnson | 2 | $25 |
| Upsher-smith Laboratories LLC | 1 | $25 |
| Genentech USA, Inc. | 1 | $23 |
| Catalyst Pharmaceuticals, Inc. | 1 | $22 |
| Resmed Corp | 1 | $20 |
| Sumitomo Pharma America, Inc. | 3 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Aprecia Pharmaceuticals, LLC | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,605
- QULIPTA$241
- UBRELVY$121
- NURTEC ODT$117
How this compares
$4,790 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 106 | $154,363 |
| BriviactBrivaracetam | 25 | $43,966 |
| AptiomEslicarbazepine Acetate | 19 | $30,332 |
| Emgality PenGalcanezumab-Gnlm | 35 | $28,537 |
| VimpatLacosamide | 26 | $28,354 |
| Lacosamide | 162 | $17,587 |
| Memantine Hcl | 377 | $14,038 |
| DilantinPhenytoin Sodium Extended | 61 | $13,536 |
| Levetiracetam | 376 | $12,708 |
| UbrelvyUbrogepant | 14 | $12,213 |
| Divalproex Sodium ErDivalproex Sodium | 66 | $9,929 |
| Gabapentin | 312 | $5,509 |
| Donepezil Hcl | 333 | $5,347 |
| Oxcarbazepine | 98 | $4,914 |
| Memantine Hcl ErMemantine Hcl | 44 | $4,668 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt, Dilantin | $138 | $167,898167 claims |
| UCB, Inc.Briviact, Vimpat | $369 | $72,32051 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $88 | $30,33219 claims |
| AbbVieUbrelvy | $714 | $12,21314 claims |
| Upsher-smith Laboratories LLCTopiramate | $25 | $3,518249 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.
Other family in Columbus
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.